Subsequently, the expression of JWA was studied using IHC, which demonstrated that JWA was less expressed in trastuzumab-resistant breast cancer tissues than in trastuzumab-sensitive tissues, suggesting that the downregulation of JWA in trastuzumab-resistant breast cancer might be associated with tumor growth. Here, ARL6IP5 is linked to breast carcinoma.